相似文献
1
Continual reassessment and related designs in dose-finding studies.
Stat Med. 2011 Jul 30;30(17):2057-61. doi: 10.1002/sim.4215. Epub 2011 Feb 24.
2
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Clin Trials. 2020 Oct;17(5):522-534. doi: 10.1177/1740774520932130. Epub 2020 Jul 7.
3
Shift models for dose-finding in partially ordered groups.
Clin Trials. 2019 Feb;16(1):32-40. doi: 10.1177/1740774518801599. Epub 2018 Oct 11.
4
The continual reassessment method for dose-finding studies: a tutorial.
Clin Trials. 2006;3(1):57-71. doi: 10.1191/1740774506cn134oa.
5
Extended model-based designs for more complex dose-finding studies.
Stat Med. 2011 Jul 30;30(17):2062-9. doi: 10.1002/sim.4024. Epub 2011 Feb 24.
6
Retrospective analysis of sequential dose-finding designs.
Biometrics. 2005 Sep;61(3):749-56. doi: 10.1111/j.1541-0420.2005.00353.x.
7
Evaluation of irrational dose assignment definitions using the continual reassessment method.
Clin Trials. 2019 Dec;16(6):665-672. doi: 10.1177/1740774519873316. Epub 2019 Sep 23.
8
How to design a dose-finding study using the continual reassessment method.
BMC Med Res Methodol. 2019 Jan 18;19(1):18. doi: 10.1186/s12874-018-0638-z.
9
Comparative review of novel model-assisted designs for phase I clinical trials.
Stat Med. 2018 Jun 30;37(14):2208-2222. doi: 10.1002/sim.7674. Epub 2018 Apr 22.
10
Incorporating lower grade toxicity information into dose finding designs.
Clin Trials. 2011 Aug;8(4):370-9. doi: 10.1177/1740774511410732.
引用本文的文献
1
A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Stat Med. 2022 Mar 15;41(6):1059-1080. doi: 10.1002/sim.9316. Epub 2022 Jan 25.
2
Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
BMC Cancer. 2021 Jan 5;21(1):7. doi: 10.1186/s12885-020-07703-6.
3
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
BMC Cancer. 2016 Aug 31;16(1):703. doi: 10.1186/s12885-016-2702-6.
4
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.
5
Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
J Clin Oncol. 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30.
6
BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY.
Ann Appl Stat. 2013 Dec 1;7(4):1837-2457. doi: 10.1214/13-AOAS661.
7
Adaptive prior variance calibration in the Bayesian continual reassessment method.
Stat Med. 2013 Jun 15;32(13):2221-34. doi: 10.1002/sim.5621. Epub 2012 Sep 17.
本文引用的文献
1
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.
Biometrics. 2010 Jun;66(2):532-40. doi: 10.1111/j.1541-0420.2009.01302.x. Epub 2009 Aug 10.
2
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
Clin Trials. 2008;5(5):465-77. doi: 10.1177/1740774508096474.
3
Translation of innovative designs into phase I trials.
J Clin Oncol. 2007 Nov 1;25(31):4982-6. doi: 10.1200/JCO.2007.12.1012.
4
The continual reassessment method for dose-finding studies: a tutorial.
Clin Trials. 2006;3(1):57-71. doi: 10.1191/1740774506cn134oa.
5
Experimental designs for phase I and phase I/II dose-finding studies.
Br J Cancer. 2006 Mar 13;94(5):609-13. doi: 10.1038/sj.bjc.6602969.
6
Retrospective analysis of sequential dose-finding designs.
Biometrics. 2005 Sep;61(3):749-56. doi: 10.1111/j.1541-0420.2005.00353.x.
7
An evaluation of phase I clinical trial designs in the continuous dose-response setting.
Stat Med. 2001 Aug 30;20(16):2399-408. doi: 10.1002/sim.903.
8
Another look at two phase I clinical trial designs.
Stat Med. 1999 Oct 30;18(20):2683-90; discussion 2691-2. doi: 10.1002/(sici)1097-0258(19991030)18:20<2683::aid-sim193>3.0.co;2-z.
9
Accrual strategies for phase I trials with delayed patient outcome.
Stat Med. 1999 May 30;18(10):1155-69. doi: 10.1002/(sici)1097-0258(19990530)18:10<1155::aid-sim114>3.0.co;2-h.
10
Bayesian decision procedures based on logistic regression models for dose-finding studies.
J Biopharm Stat. 1998 Jul;8(3):445-67. doi: 10.1080/10543409808835252.
Zotero 插件